{"id":"W2054717635","doi":"10.1111/bjd.12266","title":"A randomized phase 2a efficacy and safety trial of the topical <scp>J</scp> anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","year":2013,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":202,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; Université de Montréal; Innovaderm (Canada)","funders":"Pfizer","keywords":"Tofacitinib; Medicine; Janus kinase inhibitor; Adverse effect; Tolerability; Discontinuation; Erythema; Dermatology; Psoriasis; Plaque psoriasis; Randomized controlled trial; Clinical endpoint; Internal medicine; Pharmacology; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002628152,0.002076448,0.002569502,0.0004242357,0.0005911579,0.00134968,0.0009264868,0.001689159,0.008687427],"category_scores_gemma":[0.001567181,0.0008994195,0.001195523,0.0004685772,0.001452214,0.001140065,0.0004291555,0.003327603,0.001290334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001182984,"about_ca_system_score_gemma":0.001983846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009828007,"about_ca_topic_score_gemma":0.002271187,"domain_scores_codex":[0.999176,0.0004123332,0.00004072526,0.0001498599,0.00008832525,0.0001327499],"domain_scores_gemma":[0.9987822,0.0002383837,0.00034444,0.0001020348,0.00007815492,0.0004548269],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9654174,0.01580383,0.0007080392,0.0002452913,0.0003942079,0.00005477962,0.00004220006,0.0002415046,0.006355759,0.00009005898,0.001023796,0.009622999],"study_design_scores_gemma":[0.9212832,0.07593725,0.001306848,0.00001088142,0.0001361871,0.00005126324,0.00001460513,0.0002427943,0.0004329649,0.00008195631,0.0004929996,0.000009105284],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870804,0.002239621,0.0006334507,0.0006457814,0.0003653498,0.005755494,0.001338355,0.0001112946,0.001830233],"genre_scores_gemma":[0.9817889,0.002107716,0.001805849,0.001265108,0.0006794665,0.007367332,0.001963366,0.00004240523,0.002979815],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008687427,"threshold_uncertainty_score":0.02906239,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01371388029658441,"score_gpt":0.2499637388244977,"score_spread":0.2362498585279132,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}